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A highly sensitive and rapid method for routinely screening large numbers of donated blood units for
parvovirus B19 by the polymerase chain reaction (PCR) was developed. Over a 3-month trial period in
Edinburgh, B19 DNA was detected in 6 of 20,000 consecutive units of blood (0.03%), in concentrations ranging
from 2.4 x 104 to 5 x 1010 copies of viral DNA per ml. Seroconversion for B19-specific immunoglobulin M and
immunoglobulin G and disappearance of circulating B19 DNA occurred in the interval between donation and
recall in four of the five implicated donors who could be recalled. B19 DNA was detected in 18 of 27 separate
batches of non-heat-treated factor VIII and IX concentrate manufactured from donated plasma unscreened for
B19 DNA. Dry-heat treatment at 80°C for 72 h reduced but did not always eliminate detectable B19 from factor
VIII concentrates, consistent with recent observations that current methods for virus inactivation during blood
product manufacture are insufficient to entirely eliminate B19 infectivity. The methods developed in this study
for PCR screening could be applied routinely to prevent transfusion of B19 in blood and blood products and
could play an important role in the prevention of iatrogenic transmission of infection. PCR screening could also
be used for detection and exclusion of a range of other transmission-associated viruses for which current
serological detection methods are only partially effective.
Human parvovirus B19 normally causes an asymptomatic
or mild self-limiting infection in children (fifth disease) and a
rash and transient symmetrical polyarthralgia in adults (1,
37). More severe disease manifestations, such as aplastic
crises, have been described in those with underlying hemo-
lytic anemia or blood dyscrasias, such as sickle cell disease
(reviewed in reference 15). Exposure of immunosuppressed
individuals to B19 may lead to persistent infection, with a
chronic anemia secondary to erythrocyte aplasia (18).
Although B19 is normally spread via the respiratory route,
parenteral transmission is possible via transfusion of blood
products made from plasma pools containing blood donated
during the viremic stage of B19 infection. This occurs
approximately 7 to 9 days after exposure and precedes the
onset of symptoms by several days. Several techniques have
been used to detect parvovirus B19 viremia, including an
assay for circulating viral antigen (9), a hybridization assay
(11, 21, 23, 26), and more recently the more sensitive
polymerase chain reaction (PCR) (8, 16, 26). In this study,
we have used the PCR to measure the frequency of viremic
blood donors collected over a 3-month period and to explore
the feasibility of using this method routinely to exclude the
virus from blood products. Screening was carried out by
pooling donated blood prior to DNA extraction and PCR;
positive pools were then subdivided to identify the viremic
donors to allow recall and clinical assessment. The methods
developed in this study for the detection of parvovirus B19
can be regarded as a model for the exclusion by PCR of other





Samples. We collected 20,000 units of blood from volun-
teer donors in the Edinburgh area in the period from May to
July 1991. Aliquots (200 ,ul) of plasma from each were taken
and stored at -20°C prior to pooling and testing by PCR.
Following identification of viremic donors, plasma from
previous and follow-up donations or samples obtained on
recall of donors were tested by PCR and by B19 serology
(see below). Blood products were obtained from the U.K.
National Institute of Biological Standards and Controls
(NIBSC) and the Protein Fractionation Centre, Scottish
National Blood Transfusion Service (SNBTS), Edinburgh.
Freeze-dried preparations of factor VIII and factor IX were
stored at 4°C prior to reconstitution, and intravenous immu-
noglobulin (IgG) was stored as a reconstituted aqueous
solution (50 g/liter) at -20°C. Lyophilized vials were recon-
stituted as specified by the manufacturer at 11 and 36 U/ml
for factor VIII and factor IX, respectively, immediately
before use.
To investigate the kinetics of B19 inactivation during heat
treatment, intermediate-purity factor VIII was spiked 1:100
with B19-positive plasma, freeze-dried, and heated using
model SNBTS production cycles. Such levels of additional
proteins in intermediate-purity factor VIII have been shown
previously to have no effect on the freeze-drying or heating
characteristics of this product.
Primers. Primers PV1 to PV4 corresponded to the se-
quences of the published Wi and Au variants of parvovirus
B19 (5, 30). This region showed substantial nucleotide and
amino acid sequence homology with adeno-associated virus
(33), minute virus of mice (2), Hi (24), and feline parvovirus
(7). Sense PV1 (GGTAAGAAAAATACACTGT) and an-
tisense PV2 (TTGCCCGCCTAAAATGGC'TI) primers (5'
bases at positions 1390 and 1608, respectively, numbered as
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Pools of 500 Pools of 100 Pools of 10
15 - -599 - 600/1 -
16 - -600 + -600/2 -
17 + 601 - -600/3 +
18 - -602 - 600/4 -
19 - -603 - 600/5 -
20 + 600/6 -
21 - -600/7 -
22 - -600/8 -
23 - 600/9 -












FIG. 1. Example of the identification of B19-infected donors by sequential PCR screening. Positive pools of 500 blood units (no. 17 and
20; underlined) were retested in five pools of 100 units. Identification of pool 600 allowed rescreening in pools of 10 (showing that 600/3 was
positive) and finally the identification of the infectious donor (600/3/6).
in reference 30), separated by 180 nucleotides, were used for
the first reaction of a double PCR; PV3 (ATGGGCCGCCA
AGTACAGGAAA; position 1415) and PV4 (TCATTAA
ATGGAAAGTTTTTCATT; position 1520) were inner (nest-
ed) primers used in the second reaction. The sequences of
PV1 to PV4, although independently derived by our own
sequence comparisons, were positioned similarly to those of
primers first described by Clewley (8) and represent one of
the most highly conserved regions between different parvo-
virus genomes. Sense PV5 (AAGTlT'GCCGGAAGTTCCC
G; position 3076) and antisense PV6 (AGCATCAGGAGCT
ATACTTCC; position 3478) were used for the first reaction
of the double PCR, and PV7 (CCCAAGCATGACITCAG;
position 3118) and PV8 (TCTAAATATCTCCATGG; posi-
tion 3396) were used in the nested second reaction. Primers
PV5 to PV8 amplified part of the B19 genome encoding an
antigenic region within the B19 nucleocapsid (13).
DNA extraction. Aliquots (2 ml) of the plasma pools (made
up from 4 ,ul each of 500 blood units) were centrifuged at
100,000 x g for 2 h at 4°C. The supernatant was decanted,
and the DNA in the pellet was extracted into a final volume
of 100 ,ul of water as described previously (32). Samples
making up the pools of 500 blood units that were positive by
PCR, were reconstituted successively in pools of 100, 10,
and 1 blood unit to identify the viremic donor. DNA was
extracted from 2.5-ml volumes of reconstituted blood prod-
ucts as described above.
PCR. DNA (10 ,ul) was amplified in a nested PCR with
primers PV1 and PV2 followed by PV3 and PV4 as described
previously (32). The product of the second reaction was
examined by agarose gel electrophoresis and staining with
ethidium bromide. All PCRs were carried out with appropri-
ate positive and negative controls.
Following the identification of a positive blood unit, an
aliquot of the corresponding plasma pack was retested by
PCR. The amount of B19 DNA within the sample was
estimated by titer determination at limiting dilution, with 5 to
15 replicates tested at each 10-fold dilution (32). Sequencing
of B19 DNA amplified from positive units by using primers
PV1-PV2 and PV5-PV6 was carried out by the previously
described limiting-dilution and direct-sequencing method
(31). Sequences obtained between positions 1415 and 1584
(numbered as in reference 30) and between 3118 and 3444
were analyzed by using the University of Wisconsin Genet-
ics Computer Group package (12).
Serology. Plasma samples from PCR-positive blood units,
stored samples of previously donated blood from each
parvovirus B19-infected donor, and samples of blood col-
lected on recall were tested blind for B19-specific IgG and
IgM by capture radioimmunoassay (10).
Nucleotide sequence accession numbers. Sequences ob-
tained in this study have been submitted to GenBank under
accession numbers L05199 to L05210.
RESULTS
Blood donor screening. A total of 20,000 blood units
collected from volunteer donors over a period of approxi-
mately 3 months in southeastern Scotland were screened by
PCR in 40 separate pools of 500 units. The limit of sensitivity
of this screening method was 5 virions per ml in a pool, and
therefore 2,500 virions per ml in each component unit. On
initial screening with the primers PV1 to PV4, 6 of the 40
pools were found to contain detectable amounts of B19
DNA. All six samples were also positive on testing with
primers PV5 to PV8. To identify the viremic donors, each
original positive pool was divided into five pools of 100 units,
which were rescreened. Each set of five pools divided in this
way yielded a single PCR-positive pool of 100. The six
positive pools of 100 units were each in turn reconstituted as
10 pools of 10 donations, and each set of 10 pools produced
a single PCR-positive sample. Finally, each unit used to
make up the six positive pools of 10 was tested to identify the
six positive blood donors (pl to p6). An example of the steps
used to identify a viremic blood unit is shown in Fig. 1. The
six units of plasma corresponding to the positive samples
were recalled from the Protein Fractionation Centre, and all
were found to be PCR positive. With one exception, nucle-
otide sequences of DNA amplified with primers PV1-PV2
and PV5-PV6 from the six donors differed from published
sequences of B19 (5, 30) and from each other by 1 to 6
substitutions (Table 1). In the one instance in which two
donors yielded the same viral sequences, recall showed that
the two infections were epidemiologically linked (husband
and wife; see below). Finding different sequences in each
donor rules out the possibility that the positive results
obtained on screening were the result of inadvertent contam-
ination of samples or buffers.
The concentration of parvovirus DNA ranged from 2 x
104 to 5 x 1010 copies per ml (Table 2), the latter concentra-
tion corresponding to approximately 0.5 p,g of circulating
viral antigen per ml (35). Virus particles of diameter 22 to 25
nm, with a density of 1.41 g/cm3 in cesium chloride, were
clearly visualized by electron microscopy in the sample from
donor p5 (data not shown).
Clinical and virological studies of infected blood donors.
Previously donated blood and follow-up samples from each
of the PCR-positive blood donors were tested for B19-
specific IgG and IgM and for B19 by PCR (Fig. 2). Five of the
six individuals (pl to pS) were negative for both IgM and IgG
in all samples prior to donation, and four of the five were still
negative at the time when viremia was detected. All four of
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TABLE 1. Variation in nucleotide sequence of B19 DNA amplified from viremic blood donors
Nucleotide positiona B19-AU Nucleotide change' in:
pl p2 p3 p4 p5 p6
Region 1 (nt 1415-1584)C
1503 A G (-) G (-)
1530 A G(-) G(-) G(-) G(-) G(-)
1576 G (V) T (L)
Region 2 (nt 311853444)d
3172 G A(-) A(-)
3182 T (S) C (L) C (L) C (L) C (L) C (L) C (L)
3214 T A(-) A(-)
3223 T C(-) C (-) C(-) C (-) C (-) C (-)
3307 G A (-) A(-)
3355 C T(-) T(-) T(-) T(-) T(-) T(-)
3394 A G(-) G(-)
a Positions of variable nucleotides between blood donor samples and with the B190-AU variant, numbered as in reference 30.
b Standard single-letter codes used in parentheses to indicate variable amino acids: V, valine; L, leucine; S, serine. Minus signs in parentheses indicate silent
nucleotide substitutions.
c Region amplified by primers PV1 and PV2 (see Materials and Methods).
d Region amplified by primers PV5 and PV6 (see Materials and Methods).
those recalled subsequently became IgG positive and IgM
positive 3 to 6 months after donation. Samples from p6 were
IgG positive before, during, and after donation. No B19-
specific IgM was detected in follow-up samples from this
individual. B19 DNA was undetectable in all samples col-
lected from donors on recall (60 to 100 days after donation);
blood units donated previously by all six donors were
uniformly PCR negative.
Rash, fever, and arthropathy were reported by the two
female donors (pl and p2), whereas the male donors were
generally asymptomatic, including p5, who had extremely
high levels of circulating virus (Table 2). Two of the donors
were husband and wife (p2 and p3), and they reported
parvovirus-like symptoms of infection in other members of
their immediate family.
Detection of parvovirus B19 in blood products. The fre-
quency of PCR-positive units detected in the above study
(1/3,300) indicates that B19 might frequently contaminate
blood products in which pools of 3,000 to 10,000 plasma
units are used as raw material in the manufacturing process.
We therefore tested several blood products for B19 DNA
and investigated the effect of heat treatment on its survival in
factor VIII preparations. Of 18 non-heat-treated batches of
factor VIII and 9 non-heat-treated batches of factor IX, 13
and 7, respectively, were PCR positive with primers PV1 to
PV4 (Table 3). None of the intravenous Ig preparations
contained detectable B19 DNA.
Five PCR-positive batches of factor VIII were heat treated
by a standard manufacturing process (80°C for 72 h) and
retested. Two of the five batches remained PCR positive.
Determination of the B19 DNA titer before and after heat
treatment in the two batches that remained positive showed
at least 90% reduction in the amount of detectable viral DNA
(Table 4). To investigate the kinetics of virus inactivation,
we spiked a batch of factor VIII 1:100 with plasma from
donor p5. During lyophilization, the viral DNA titer declined
from 4.5 x 108 to 7 x 107 copies per ml. The lyophilized
material was then subjected to dry-heat treatment for 24, 48,
and 72 h at 80°C; a reduction to the final titer of 8 x 106
6
5
TABLE 2. Clinical symptoms and B19 DNA titers
in viremic blood donors
No. of
Donor Agr) Sex' Symptoms copies of
B19 DNA/ml
pl 19 F Rash, fever, arthropathy 4 x 105
14 days postdonation
p2 35 F Rash, fever, arthropathy 2.5 x 10
5-6 days postdonation;
rash recurred after 1 mo
p3 36 M Asymptomatic 4 x 104
p4 30 M Asymptomatic 2 x 107
p5 36 M Asymptomatic 5 x 1010
p6 35 M Tired with occasional joint 5 x 104
pains over several
months before and after
donation
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FIG. 2. Time course of the appearance of anti-B19-specific IgM
and IgG in donors identified as viremic on screening by PCR.
Symbols: O, anti-B19 IgG and IgM negative; El, anti-B19 IgM and
IgG positive; *, anti-B19 IgG positive and IgM negative. All donors
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TABLE 3. Frequency of detection of B19 in blood products
Blood product Source Heat No. positive/treateda no. tested
Factor VIII NIBSC No 4/8
SNBTS No 7/10
SNBTS Yes 2/5
Factor IX NIBSC No 3/4
SNBTS No 4/5
Intravenous IgG SNBTS No 0/10
a Dry-heat treatment for 72 h at 80'C.
copies per ml occurred during this process (Table 5). The
98% overall reduction in viral DNA titer is comparable to
that observed on heat treatment of nonspiked samples (Table
4).
DISCUSSION
Detection of B19 infection in blood donors. The incidence of
B19 viremia in healthy blood donors in this study was
approximately 1/3,300, considerably higher than that re-
ported by previous surveys in which antigen detection
methods were used (9, 22). This presumably reflects the
greater sensitivity of the PCR. Blood units containing less
than 106 copies, equivalent to approximately 5 pg of viral
antigen (as occurred in four of the six positive samples
identified in this study) would be unlikely to have been
detected by the most sensitive enzyme-linked immunosor-
bent assay-based methods. Hybridization methods typically
detect 0.1 to 1 pg of B19 DNA (corresponding to approxi-
mately 2 x 104 to 2 x 105 copies). A hybridization assay with
a chemiluminescent probe showed a sensitivity of 20 fg of
B19 DNA, or 4,000 copies (23), but even this method would
not have been suitable for testing large pools because it is
considerably less sensitive than the PCR (5 copies per ml of
plasma). The PCR also enabled us to carry out direct
sequence analysis of amplified DNA and thus to make a
positive identification of B19 sequences and distinguish B19
from other parvoviruses. Minor variations in sequence be-
tween B19 in different blood units confirmed that we had
selected five independent B19 infections in the six donors.
Sequence variability in the VP2 region was comparable to
that observed among other epidemiologically unrelated iso-
lates of B19 (34).
All viremic individuals were asymptomatic at the time of
donation, and three of four male donors remained asymp-
tomatic. Symptoms of rash and arthropathy similar to those
reported in previous studies of adult infection (1, 37) were
reported in both female donors in the following 5 to 14 days.
A higher rate of symptomatic infection in women has been
TABLE 4. Effect of heat treatment' on levels of B19 DNA in
factor VIII concentrate
No. of copies of B19 DNA/ml
Batch Before After % Reduction
treatment treatment
1 500 <22 >95
2 50 <22 >55
3 340 <22 >93
4 1,900 170 91
5 1,400 50 96
a Dry-heat treatment at 80'C for 72 h.
TABLE 5. Kinetics of B19 DNA removal during heat
treatment of factor VIII
Sample No. of copies of % ReductionB19 DNA/mi
Spiked factor VIII 4.5 x 108
After lyophilization 7 x 107 85
24 h at 80'C' 2.5 x 107 95
48 h at 80'C 2 x 107 96
72 h at 80'C 8 x 106 98
a Dry-heat treatment.
reported previously (37). Four of the five donors recalled
showed a specific IgM and IgG response to B19 following
donation, consistent with a primary infection (1, 10). Donor
p6 was unusual in that he was anti-B19 IgG positive before
donation and before the time of viremia and no IgM was
detected at or after donation. Reinfection with parvovirus is
one possible explanation; in a previous study, experimental
inoculation of a healthy adult volunteer with a low level of
anti-B19 IgG led to reinfection, manifested by a second IgM
response and increased levels of anti-B19 IgG (1). However,
neither serological response was observed in the blood
donor in this study. Interestingly, this individual had com-
plained of recurrent polyarthralgia for several months both
before and after donation. It is possible that he had a
chronic, low-grade infection with subclinical reactivation of
B19 at the time of donation.
Parvovirus contamination ofblood products. B19 DNA was
detected in two-thirds of the batches of noninactivated
clotting-factor concentrates tested. This might be expected
given the frequency of viremic donors, the size of the pools
used for manufacture (3,000 to 10,000 plasma units), and the
fractionation process used (28). Whether these blood prod-
ucts are infectious depends on the stability of the virus, the
possible neutralization of infectivity by mixture with anti-
body from other units in the pool (17), and the partitioning of
the virus during cryoprecipitation and cold ethanol precipi-
tation during manufacture.
There is convincing serological evidence for transmission
of B19 by non-heat-treated factor VIII and prothrombin
complex concentrates (22, 25, 36). Clinical data on recipients
concerning the infectivity of "virally inactivated" concen-
trates are contradictory and may reflect variation in the
precise conditions used for virus removal. In one study,
serological testing of hemophiliacs who had received factor
VIII subjected to dry-heat treatment for 72 h at 80°C showed
that they had no increased risk of infection over age-matched
controls (36). However, elevated rates of infection were
found in recipients of dry heat-treated or steam-treated
factor VIII (4). Furthermore, previously nontransfused he-
mophiliacs have been observed to become acutely infected 7
to 14 days after the first infusion of detergent-treated (3, 20)
or heat-treated (3, 4, 19) clotting factor. The persistence of
B19 DNA in factor VIII concentrates found in this study
after heat treatment for 72 h at 80°C does not necessarily
indicate continued infectivity. However, these results con-
trast with the studies of other viruses, such as hepatitis C
virus, in which the same treatment not only apparently
eliminates infectivity but also completely destroys all traces
of viral nucleic acid (14). More precise studies of B19
inactivation by different treatment regimens await infectivity
studies with recently developed in vitro culture systems for
B19 (6, 29).
Feasibility of donor screening by PCR. The identification of
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a PCR-positive blood unit required four sequential separate
DNA extraction and nested amplification reactions. How-
ever, plasma making up the initial pools of 500 found to be
negative (34 of the 40 tested) could have been safely trans-
fused after only one amplification reaction. An insignificant
proportion of units (in this study, 54 of 20,000) would require
four screens by PCR to rule out contamination. In this study,
no attempt was made to optimize the time taken for DNA
extraction and PCR. Despite this, we managed to retrieve all
six units of infected plasma from the Protein Fractionation
Centre before manufacture. As the DNA extraction and
amplification steps could be carried out within a single
working day, we could also have prevented transfusion of all
contaminated units of erythrocytes and platelets with a
minimal effect on the time taken from collection to blood
issue. However, routine application of this method for virus
detection in donor centers would be greatly facilitated by
methods for rapid DNA extraction and automation of the
amplification reactions; such methods are currently being
developed.
As well as greatly reducing the risk of parvovirus B19
infection of susceptible individuals, with its attendant com-
plications, this method of screening could be used to sup-
plement serological screening for other transfusion-transmit-
ted viruses, notably hepatitis B virus, for which continued
transmission of infection occurs from hepatitis B surface
antigen-negative blood.
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